DITTO Daily's PhD-Designed Supplement Convinced 88% of Trial Participants

For a market saturated with wellness promises, the most compelling signal is often a simple percentage. In a clinical trial for DITTO Daily’s flagship product, 88% of participants reported a reduction in overall menstrual symptom severity [BusinessCloud, Unknown]. Another 88% agreed they experienced fewer mood changes by the third cycle [Citruslabs, Unknown]. Those figures, while from a single study, are the foundation of a young company’s bet that rigorous science can carve a durable space in the crowded direct-to-consumer supplement aisle.

Founded in 2024 by PhD nutrition scientist Alice van der Schoot, DITTO Daily sells a daily Cycle Supplement formulated to address cramps, fatigue, bloating, and hormonal acne [Nutraceutical Business Review, Unknown]. The company’s early £1.35 million pre-seed round, led by Eka Ventures, suggests investors see potential in a research-led approach to a pervasive, often under-served health concern [Raising.fi, August 2025]. The challenge now is translating a compelling clinical signal into sustainable consumer trust and scale.

The PhD in the formulation

DITTO’s central differentiator is inextricably linked to its founder. Alice van der Schoot is not a marketer who later sought scientific validation; she is a nutrition scientist whose PhD research at King’s College London investigates dietary interventions and immune response [King’s College London, Unknown]. This background informs the company’s ‘PhD-designed’ branding and its public communications, which frequently examine into the mechanistic links between nutrients and symptoms like neurotransmitter function in PMS and PMDD [The Endo Belly Coach, Unknown].

The formulation itself leans on this expertise, employing what the company calls advanced beadlet technology aimed at enhancing ingredient absorption [Nutraceutical Business Review, Unknown]. While the supplement market is lightly regulated compared to pharmaceuticals, DITTO’s strategy is to build credibility through transparency about ingredient provenance and the cited clinical outcomes. This positions the brand against generic multivitamins and less substantiated ‘women’s wellness’ products, aiming for a consumer who is skeptical of anecdotal claims.

Traction beyond the trial

Clinical data provides the wedge, but commercial traction requires audience building. DITTO Daily has cultivated a significant social media presence, reportedly amassing more than 116,000 followers across Instagram and TikTok [Women Entrepreneurs Review, Unknown]. This channel serves as both a direct sales funnel and a platform for van der Schoot to amplify the brand’s science-led narrative through podcast appearances and educational content [The Endo Belly Coach, Unknown].

The business model is classic DTC, with subscriptions and one-off purchases available through its website [dittodaily.com, Unknown]. The early funding is earmarked for scaling this operation, though specific revenue or customer count figures are not yet public. The company’s team, as noted on LinkedIn, includes van der Schoot alongside Anita Mitra and Dr. Tosin Sotubo-Ajayi, suggesting a focus on combining scientific and operational expertise [Alice van der Schoot - DITTO DAILY | LinkedIn, 2026].

The competitive and regulatory landscape

DITTO Daily operates in a competitive segment where branding and perceived efficacy are paramount. The company’s most direct analogue may be Perelel Health, a US-based brand also founded by women with a focus on life-stage-specific supplement packs. The broader competitive set includes countless over-the-counter options and a growing number of digital health platforms offering holistic care. DITTO’s answer is its concentrated focus on cycle-specific symptoms and its founder’s credentialed voice.

The regulatory context for supplements, however, introduces a persistent risk. Unlike drugs, these products do not require pre-market FDA or EMA approval for efficacy. Claims are monitored post-market, placing the burden of trust-building entirely on the company. DITTO’s published trial data is a strong step, but maintaining scientific integrity while scaling marketing and facing inevitable copycats will be an ongoing test. The company’s reliance on a single flagship product also concentrates its commercial risk.

• Clinical validation. The 88% symptom reduction figure is a powerful early signal, but it comes from a single study. Replicating these results in larger, independent trials will be crucial for long-term credibility.
• Customer acquisition cost. The DTC supplement space is notoriously expensive for customer acquisition. DITTO’s social following is an asset, but converting followers into retained subscribers at a positive lifetime value is the unsolved equation for many in the category.
• Market expansion. The company is currently UK-focused. Scaling into new geographic markets, each with its own regulatory nuances and competitive landscapes, presents a significant operational hurdle.

The patient population and standard of care

For the millions of people managing menstrual symptoms, the current standard of care is often a fragmented and frustrating patchwork. It typically involves over-the-counter pain relievers for cramps, a trial-and-error approach with various vitamins, and, for more severe cases, prescription hormonal therapies like birth control. Many navigate this without ever consulting a specialist, due to gaps in healthcare access or the historical dismissal of menstrual pain. The result is a vast population self-managing with tools that are frequently inadequate or accompanied by undesirable side effects.

DITTO Daily is targeting this exact group: individuals seeking a non-prescription, daily intervention for core hormonal symptoms like cramps, mood swings, and fatigue [Nutraceutical Business Review, Unknown]. The company’s premise is that a precisely formulated, evidence-backed supplement can offer a more effective and consistent layer of support within this self-care paradigm. The next twelve months will reveal whether that premise, backed by early trial data and founder credibility, can secure a lasting place in the daily routines of that patient population.

Sources

1. [BusinessCloud, Unknown] DITTO Daily clinical trial results | https://www.businesscloud.co.uk/
2. [Citruslabs, Unknown] DITTO Daily trial data on mood changes | https://citruslabs.com/
3. [Nutraceutical Business Review, Unknown] DITTO Daily product formulation and technology | https://www.nutraceuticalbusinessreview.com/
4. [Raising.fi, August 2025] DITTO Daily raises £1.35 million pre-seed round | https://raising.fi/company/dittodaily
5. [King’s College London, Unknown] Alice van der Schoot PhD research profile | https://www.kcl.ac.uk/
6. [The Endo Belly Coach, Unknown] Podcast with Alice van der Schoot on evidence-based nutrients | https://www.theendobellycoach.com/podcast/evidence-based-nutrients-for-endo-ditto
7. [Women Entrepreneurs Review, Unknown] DITTO Daily social media following | https://www.womenentrepreneursreview.com/news/women-led-startup-ditto-daily-rises-135m-pound-in-pre-seed-round-headed-by-eka-ventures-nwid-7216.html
8. [dittodaily.com, Unknown] DITTO Daily official website and store | https://dittodaily.com
9. [Alice van der Schoot - DITTO DAILY | LinkedIn, 2026] DITTO Daily team information | https://uk.linkedin.com/in/alice-van-der-schoot-957358371